Add to ORKGmTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease – a combined tissue microarray, in vitro correlation beetween mTOR activity and different clinical data of HL patients, such as survival. We also found that Márk et al. BMC Cancer 2013, 13:25
The mechanistic/mammalian target of rapamycin (mTOR), a serine/threonine kinase, is a central regula...
which permits unrestricted use, distribution, and reproduction in any medium, provided the original ...
The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a treatment benefi...
BACKGROUND: Targeting signaling pathways is an attractive approach in many malignancies. The PI3K/Ak...
Diffuse large B-cell lymphoma is a heterogeneous group of diseases with different responses to thera...
Despite impressive treatment advances, few options for refractory or relapsed Hodgkin Lymphoma (HL) ...
The activity of the mechanistic target of rapamycin (mTOR) is elevated in various types of human can...
Growing evidence identified deregulation of signalling elements of Notch and mammalian target of rap...
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive blood malignancy that arises from the c...
The content of this article has been reviewed by independent peer reviewers to ensure that it is bal...
Objective: The mTOR pathway could be a promising target for treatment of ovarian cancer. As it seems...
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common malignancy worldwide. There i...
<div><p>Background</p><p>Patients infected with HIV have a significantly increased risk of developin...
Nousheen Samad1, Anas Younes21Division of Pharmacy, Pharmacy Clinical Programs, 2Department of Lymph...
Background & Aims: The advent of targeted therapies in hepatocellular carcinoma (HCC) has underscore...
The mechanistic/mammalian target of rapamycin (mTOR), a serine/threonine kinase, is a central regula...
which permits unrestricted use, distribution, and reproduction in any medium, provided the original ...
The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a treatment benefi...
BACKGROUND: Targeting signaling pathways is an attractive approach in many malignancies. The PI3K/Ak...
Diffuse large B-cell lymphoma is a heterogeneous group of diseases with different responses to thera...
Despite impressive treatment advances, few options for refractory or relapsed Hodgkin Lymphoma (HL) ...
The activity of the mechanistic target of rapamycin (mTOR) is elevated in various types of human can...
Growing evidence identified deregulation of signalling elements of Notch and mammalian target of rap...
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive blood malignancy that arises from the c...
The content of this article has been reviewed by independent peer reviewers to ensure that it is bal...
Objective: The mTOR pathway could be a promising target for treatment of ovarian cancer. As it seems...
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common malignancy worldwide. There i...
<div><p>Background</p><p>Patients infected with HIV have a significantly increased risk of developin...
Nousheen Samad1, Anas Younes21Division of Pharmacy, Pharmacy Clinical Programs, 2Department of Lymph...
Background & Aims: The advent of targeted therapies in hepatocellular carcinoma (HCC) has underscore...
The mechanistic/mammalian target of rapamycin (mTOR), a serine/threonine kinase, is a central regula...
which permits unrestricted use, distribution, and reproduction in any medium, provided the original ...
The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a treatment benefi...